EURASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES
Innovative Academy Research Support Center
IF = 9.2 www.in-academy.uz/index.php/ejmns

CLINICAL AND PHARMACOLOGICAL APPROACH TO THE TREATMENT OF HYPERTENSION DURING PREGNANCY

Akhmedov Bahodir Urolovich
Andijan State Medical Institute
Department of Pharmacology, Clinical Pharmacology and Medical Biotechnology
https://doi.org/10.5281/zenodo.19483636

ARTICLE INFO

Received: 01st April 2026
Accepted: 08th April 2026
Online: 09th April 2026

KEYWORDS

Pregnancy, hypertension, preeclampsia, antihypertensive therapy, pharmacology, maternal-fetal safety, clinical management.

ABSTRACT

Hypertension during pregnancy is a common condition that can lead to serious complications for both the mother and the fetus. This condition includes chronic hypertension, gestational hypertension, and preeclampsia. Optimal treatment should aim to maintain maternal cardiovascular stability while ensuring fetal safety. This article analyzes clinical and pharmacological approaches to the management of hypertension during pregnancy, as well as the most effective and safe medications (labetalol, methyldopa, nifedipine). The results of the study show that these drugs effectively reduce blood pressure while maintaining the safety of both mother and fetus. In addition, the importance of developing individualized treatment plans and conducting continuous maternal-fetal monitoring is emphasized.

КЛИНИКО-ФАРМАКОЛОГИЧЕСКИЙ ПОДХОД К ЛЕЧЕНИЮ ГИПЕРТОНИИ ВО ВРЕМЯ БЕРЕМЕННОСТИ

Ахмедов Баҳодир Уролович
Андижанский государственный медицинский институт
Кафедра фармакологии, клинической фармакологии и медицинской биотехнологии
https://doi.org/10.5281/zenodo.19483636

ARTICLE INFO

Received: 01st April 2026
Accepted: 08th April 2026
Online: 09th April 2026

KEYWORDS

Беременность, гипертензия, преэклампсия, антигипертензивная терапия, фармакология, безопасность матери и плода, клиническое ведение.

ABSTRACT

Артериальная гипертензия во время беременности является распространённой проблемой, которая может привести к серьёзным осложнениям как для матери, так и для плода. Данное состояние включает хроническую гипертензию, гестационную гипертензию и преэклампсию. Оптимальное лечение должно быть направлено на поддержание сердечно-сосудистой стабильности матери и обеспечение безопасности плода. В данной статье анализируются клинические и фармакологические подходы к лечению гипертензии во время беременности, а также наиболее эффективные и безопасные лекарственные

EURASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES
Innovative Academy Research Support Center
IF = 9.2 www.in-academy.uz/index.php/ejmns

средства (лабеталол, метилдопа, нифедипин). Результаты исследования показывают, что эти препараты эффективно снижают артериальное давление, обеспечивая безопасность матери и плода. Также подчёркивается необходимость разработки индивидуальных схем лечения и проведения мониторинга состояния матери и плода.

XOMILADORLIK DAVRIDA GIPERTONIYA KASALLIGINI DAVOLASHDA KLINIK – FARMAKOLOGIK YONDASHUV

Axmedov Bahodir Urolovich
Andijon davlat tibbiyot instituti Farmakologiya, klinik farmakologiya va tibbiyot biotexnologiyalari kafedrasi
https://doi.org/10.5281/zenodo.19483636

ARTICLE INFO

Received: 01st April 2026
Accepted: 08th April 2026
Online: 09th April 2026

KEYWORDS

Xomiladorlik, gipertoniya, preeklampsiya, antihipertenziv terapiya, farmakologiya, ona-homila xavfsizligi, klinik boshqaruv.

ABSTRACT

Xomiladorlik davrida gipertoniya kasalligi ona va bola uchun jiddiy asoratlar keltirib chiqaradigan keng tarqalgan muammo hisoblanadi. Ushbu holat surunkali gipertoniya, homiladorlik davridagi gipertoniya va preeklampsiya shakllarini o‘z ichiga oladi. Optimal davolash ona kardiovaskulyar barqarorligini saqlash va homila xavfsizligini ta’minlashga qaratilgan bo‘lishi kerak. Ushbu maqolada xomiladorlik davrida gipertoniya kasalligini davolashda klinik va farmakologik yondashuvlar, eng samarali va xavfsiz dori vositalari (labetalol, metildopa, nifedipin) tahlil qilinadi. Tadqiqot natijalari ushbu preparatlar qon bosimini samarali pasaytirishini, ona va homila xavfsizligini ta’minlashini ko‘rsatadi. Shuningdek, individual davolash rejalarini ishlab chiqish va ona-homila monitoringini olib borish zarurligi ta’kidlanadi.

Introduction. Hypertensive disorders during pregnancy represent one of the most complex clinical scenarios, as two distinct physiological systems—maternal and fetal—coexist simultaneously, each with unique pharmacological sensitivities. Conditions such as chronic hypertension, gestational hypertension, preeclampsia, and eclampsia require timely diagnosis and therapeutically justified interventions. Such management is essential to prevent complications including placental insufficiency, intrauterine growth restriction, stroke, and maternal mortality [1]. In the treatment of hypertension, it is essential to reduce blood pressure while ensuring the safety of both mother and fetus. When selecting pharmacological therapy, considerations include drug safety, efficacy, and fetal protection throughout pregnancy. Additionally, non-pharmacological measures such as diet, physical activity,

and regular monitoring play a crucial role in the management process. Recent research and advances in pharmacology have enabled optimization of maternal–fetal outcomes.

Hypertension during pregnancy is a multifactorial condition closely linked to endothelial dysfunction, placental ischemia, excessive inflammatory responses, and impaired vascular reactivity. Understanding these mechanisms is critical for pharmacological management, as different classes of antihypertensive drugs target specific pathophysiological pathways. For example, beta-blockers reduce cardiac output, calcium channel blockers relax vascular smooth muscle, and central α-agonists decrease sympathetic nervous system activity.

However, management in pregnancy goes beyond conventional pharmacological logic, as fetal drug exposure, placental drug transfer, and potential developmental toxicity must also be considered. Drug selection must carefully balance therapeutic necessity against possible teratogenic or fetotoxic effects, which makes some widely used antihypertensive agents unsuitable for pregnant patients [2].

Materials and Methods. The study was conducted between 2023 and 2025 in the obstetrics and gynecology department of the Andijan Regional Maternity Complex. A total of 80 pregnant women (gestational age 20–36 weeks) with confirmed hypertension were enrolled. Participants were divided into the following groups: group I (n=40): patients receiving first-line antihypertensive therapy (labetalol or methyldopa). Group II (n=40): patients managed with non-pharmacological approaches and second-line therapy when necessary.

Patients were evaluated using clinical history, blood pressure measurements, laboratory tests (renal and liver function, proteinuria), and fetal monitoring (ultrasound and Doppler). Blood pressure was monitored daily, and maternal–fetal outcomes were observed. Statistical analysis was performed using the Student's t-test and the χ^2 test, with significance set at $p < 0.05$.

Various antihypertensive drugs were administered to the patients, and their outcomes were compared. For example, beta-blockers (such as atenolol, metoprolol, bisoprolol) reduce heart rate, cardiac output, and renin secretion through beta-1 receptor antagonism. They are indicated for patients with coexisting ischemic heart disease, arrhythmias, or heart failure with reduced ejection fraction [1]. During pregnancy, the most commonly used antihypertensive agents include alpha- and beta-blockers, calcium channel blockers (vasoselective), centrally acting antihypertensives, and certain drugs with myotropic (direct smooth muscle) effects.

Analysis and Discussion. In Group I, treatment with labetalol and methyldopa led to a significant reduction in blood pressure, with clinical improvement observed within 3–5 days. These medications are pharmacokinetically safe for the fetus and do not impair uteroplacental perfusion. In Group II, management with non-pharmacological approaches alone did not produce significant results,

highlighting the necessity of timely pharmacotherapy. Monitoring of maternal renal and liver function confirmed the safety of the medications, and no serious fetal complications were observed.

Compared with the literature, Magee et al. (2014) reported that methyldopa is the safest and most effective medication during pregnancy. Nifedipine, on the other hand, is used for rapid blood pressure reduction. ACE inhibitors and angiotensin receptor blockers are contraindicated due to their teratogenicity. From a pathophysiological perspective, the primary goals of treatment are to reduce peripheral vascular resistance, improve endothelial function, and prevent serious maternal complications such as eclampsia, stroke, and heart failure. Furthermore, international experience demonstrates that effective management of hypertension during pregnancy depends on comprehensive diagnostic protocols, timely initiation of therapy, and continuous monitoring. The guidelines of the National Institute for Health and Care Excellence (NICE), American College of Obstetricians and Gynecologists (ACOG), and World Health Organization (WHO) emphasize early risk assessment and prioritize stabilizing maternal condition while preventing fetal compromise [2].

Results. In Group I, 85% of patients achieved the target blood pressure (<140/90 mmHg). Proteinuria stabilized, and no cases of severe preeclampsia were observed. Fetal growth and Doppler parameters remained within the normal range.

In Group II, only 50% of patients reached the target blood pressure, and some required initiation of pharmacotherapy. Mild intrauterine growth restriction was observed in 10% of cases. Statistical analysis showed a significant difference between the groups ($p < 0.05$), confirming the effectiveness of timely pharmacological intervention.

Labetalol, nifedipine, and methyldopa, which are recommended worldwide as first-line antihypertensive agents, have established fetal safety profiles, supported by cohort studies conducted in multiple countries. Labetalol is often preferred due to its combined α- and β-blocking effects, providing stable blood pressure control without significantly impairing uteroplacental blood flow. Nifedipine, a calcium channel blocker, is effective both in acute hypertensive crises and for long-term management, offering rapid vasodilation and improved placental perfusion. Methyldopa, although an older medication, remains valuable because of its long-established safety record and minimal impact on fetal development. These characteristics highlight the critical importance of long-term pharmacovigilance in confirming drug safety during pregnancy.

Another important aspect is individualized (personalized) therapy. Genetic factors, comorbidities such as gestational diabetes or autoimmune disorders, and even maternal diet can influence treatment efficacy. Precision pharmacology—although still under development in obstetrics—aims to tailor antihypertensive therapy by analyzing metabolic profiles and genetic

polymorphisms that affect drug metabolism. Recent studies indicate that genetic polymorphisms in CYP3A5, CYP2D6, and β-adrenergic receptors may influence responses to nifedipine and labetalol. This suggests promising potential for personalized treatment approaches in pregnant populations [3].

Pharmacogenetic testing is not yet widely used in hypertension management; however, ongoing research suggests that it may be implemented in the future, particularly for patients with drug intolerance or treatment-resistant hypertension. As polygenic risk assessment methods advance, clinicians may eventually be able to predict both blood pressure responsiveness to specific drug classes and the long-term cardiovascular benefits [4].

Conclusions. Labetalol, methyldopa, and nifedipine demonstrate high efficacy and safety in the treatment of hypertension during pregnancy. Non-pharmacological approaches alone are insufficient for moderate to severe cases. When selecting therapy, maternal comorbidities, gestational age, and the pharmacodynamic properties of the drugs must be considered. Maternal and fetal monitoring allows for early detection of serious complications and improves outcomes.

Applying evidence-based clinical guidelines and developing individualized treatment plans ensures maternal and fetal safety. Recent advances in drug formulation have further improved patient adherence and therapeutic effectiveness. For example, sustained-release and extended-release formulations—such as nifedipine GITS (gastrointestinal therapeutic system)—provide stable 24-hour blood pressure control, reduce fluctuations, and minimize side effects like hypotension or tachycardia [5].

At the same time, the clinical-pharmacological management of hypertension in pregnant women requires a precise, safety-focused, and individualized approach. A thorough understanding of the physiological changes unique to pregnancy, selection of antihypertensive agents with proven fetal safety, avoidance of contraindicated medications, and adherence to international clinical guidelines form the foundation of rational therapy. The primary goal is not merely to lower blood pressure, but also to improve maternal overall health, protect fetal development, prevent complications, and ensure long-term cardiovascular well-being.

Enhancing clinical protocols, expanding access to safe medications, and incorporating modern technologies along with individualized pharmacology approaches can significantly improve maternal–fetal outcomes worldwide. Future research should focus on optimizing drug regimens and identifying pharmacogenomic factors to further refine personalized therapy..

References:

1. Magee L.A., von Dadelszen P., Stones W., Mathai M. The FIGO Textbook of Pregnancy Hypertension. International Journal of Gynecology & Obstetrics. 2014;127:211–223.

2. American College of Obstetricians and Gynecologists (ACOG). Hypertension in Pregnancy. ACOG Practice Bulletin No. 222. 2020.
3. Odiljonova Aziza Bakhtiyorjon kizi Clinical pharmacology of antihypertensive drugs used in the treatment of hypertension. Journal of Effective Learning and Sustainable Innovation. 2025;437-443. Uzbekistan, ASMI.
4. Rakhmonova Khosiyat Shavkatbek kizi Clinical pharmacological approach to the use of antihypertensive drugs in pregnant women. Web of Scientist: International Scientific Research Journal. 2025;141-145. Uzbekistan, ASMI.
5. Sibai B.M., Dekker G., Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785–799.
6. Easterling T.R., Carr D.B. Pharmacologic treatment of chronic hypertension in pregnancy. Semin Perinatol. 2000;24:80–87.
7. Nageotte M.P., Conrad K.P., Lindheimer M.D. Antihypertensive therapy in pregnancy. Clin Perinatol. 2016;43:173–189.
8. Abalos E., Duley L., Steyn D.W., et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2018;10:CD002252.